These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 15964198)

  • 1. Transcriptional repression and cell death induced by nuclear aggregates of non-polyglutamine protein.
    Fu L; Gao YS; Sztul E
    Neurobiol Dis; 2005 Dec; 20(3):656-65. PubMed ID: 15964198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear aggresomes form by fusion of PML-associated aggregates.
    Fu L; Gao YS; Tousson A; Shah A; Chen TL; Vertel BM; Sztul E
    Mol Biol Cell; 2005 Oct; 16(10):4905-17. PubMed ID: 16055507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human cytomegalovirus UL97 kinase prevents the deposition of mutant protein aggregates in cellular models of Huntington's disease and ataxia.
    Tower C; Fu L; Gill R; Prichard M; Lesort M; Sztul E
    Neurobiol Dis; 2011 Jan; 41(1):11-22. PubMed ID: 20732421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel GTPase, CRAG, mediates promyelocytic leukemia protein-associated nuclear body formation and degradation of expanded polyglutamine protein.
    Qin Q; Inatome R; Hotta A; Kojima M; Yamamura H; Hirai H; Yoshizawa T; Tanaka H; Fukami K; Yanagi S
    J Cell Biol; 2006 Feb; 172(4):497-504. PubMed ID: 16461359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PML clastosomes prevent nuclear accumulation of mutant ataxin-7 and other polyglutamine proteins.
    Janer A; Martin E; Muriel MP; Latouche M; Fujigasaki H; Ruberg M; Brice A; Trottier Y; Sittler A
    J Cell Biol; 2006 Jul; 174(1):65-76. PubMed ID: 16818720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promyelocytic leukemia protein is redistributed during the formation of intranuclear inclusions independent of polyglutamine expansion: an immunohistochemical study on Marinesco bodies.
    Kumada S; Uchihara T; Hayashi M; Nakamura A; Kikuchi E; Mizutani T; Oda M
    J Neuropathol Exp Neurol; 2002 Nov; 61(11):984-91. PubMed ID: 12430715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recruitment of human cytomegalovirus immediate-early 2 protein onto parental viral genomes in association with ND10 in live-infected cells.
    Sourvinos G; Tavalai N; Berndt A; Spandidos DA; Stamminger T
    J Virol; 2007 Sep; 81(18):10123-36. PubMed ID: 17626080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation.
    Schaffar G; Breuer P; Boteva R; Behrends C; Tzvetkov N; Strippel N; Sakahira H; Siegers K; Hayer-Hartl M; Hartl FU
    Mol Cell; 2004 Jul; 15(1):95-105. PubMed ID: 15225551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of the Zac1's transactivation and coactivation functions via PML and Daxx within distinct subcellular localizations.
    Ho CL; Huang YC; Tai CK; Liu ST; Wang JK; Wang WM; Huang SM
    Int J Biochem Cell Biol; 2010 Jun; 42(6):902-10. PubMed ID: 20097304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanoparticle-induced cell culture models for degenerative protein aggregation diseases.
    Chen M; von Mikecz A
    Inhal Toxicol; 2009 Jul; 21 Suppl 1():110-4. PubMed ID: 19558242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranuclear ataxin1 inclusions contain both fast- and slow-exchanging components.
    Stenoien DL; Mielke M; Mancini MA
    Nat Cell Biol; 2002 Oct; 4(10):806-10. PubMed ID: 12360291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyglutamine aggregation in Huntington's disease and spinocerebellar ataxia type 3: similar mechanisms in aggregate formation.
    Seidel K; Siswanto S; Fredrich M; Bouzrou M; Brunt ER; van Leeuwen FW; Kampinga HH; Korf HW; Rüb U; den Dunnen WF
    Neuropathol Appl Neurobiol; 2016 Feb; 42(2):153-66. PubMed ID: 26095752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nature of the nuclear inclusions formed by PQBP1, a protein linked to neurodegenerative polyglutamine diseases.
    Nicolaescu E; Beullens M; Lesage B; Keppens S; Himpens B; Bollen M
    Eur J Cell Biol; 2008 Oct; 87(10):817-29. PubMed ID: 18599155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of protein composition in specifying nuclear inclusion formation in polyglutamine disease.
    Chai Y; Wu L; Griffin JD; Paulson HL
    J Biol Chem; 2001 Nov; 276(48):44889-97. PubMed ID: 11572863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential of indole and a synthetic derivative for polyQ aggregation reduction by enhancement of the chaperone and autophagy systems.
    Lin CH; Wu YR; Kung PJ; Chen WL; Lee LC; Lin TH; Chao CY; Chen CM; Chang KH; Janreddy D; Lee-Chen GJ; Yao CF
    ACS Chem Neurosci; 2014 Oct; 5(10):1063-74. PubMed ID: 25197952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of heat shock proteins during polyglutamine neurodegeneration: mechanisms and hypothesis.
    Wyttenbach A
    J Mol Neurosci; 2004; 23(1-2):69-96. PubMed ID: 15126694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear polyglutamine-containing protein aggregates as active proteolytic centers.
    Chen M; Singer L; Scharf A; von Mikecz A
    J Cell Biol; 2008 Feb; 180(4):697-704. PubMed ID: 18283109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription.
    Shimohata T; Nakajima T; Yamada M; Uchida C; Onodera O; Naruse S; Kimura T; Koide R; Nozaki K; Sano Y; Ishiguro H; Sakoe K; Ooshima T; Sato A; Ikeuchi T; Oyake M; Sato T; Aoyagi Y; Hozumi I; Nagatsu T; Takiyama Y; Nishizawa M; Goto J; Kanazawa I; Davidson I; Tanese N; Takahashi H; Tsuji S
    Nat Genet; 2000 Sep; 26(1):29-36. PubMed ID: 10973244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aqueous extract of Gardenia jasminoides targeting oxidative stress to reduce polyQ aggregation in cell models of spinocerebellar ataxia 3.
    Chang KH; Chen WL; Wu YR; Lin TH; Wu YC; Chao CY; Lin JY; Lee LC; Chen YC; Lee-Chen GJ; Chen CM
    Neuropharmacology; 2014 Jun; 81():166-75. PubMed ID: 24486383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient mutations alter ATRX targeting to PML nuclear bodies.
    Bérubé NG; Healy J; Medina CF; Wu S; Hodgson T; Jagla M; Picketts DJ
    Eur J Hum Genet; 2008 Feb; 16(2):192-201. PubMed ID: 17957225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.